Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary
November 11, 2020
Earnings Call Speaker Segments
Jennifer Good
executiveThanks. Good afternoon, everybody, and welcome to the earnings call for our third quarter. During the quarter, we kept executing against our business plans, adjusting to the difficulties created by the COVID pandemic. So, taking a moment to look back and remind all of you about Trevi's growth strategy: we developed Haduvio, which is an oral extended-release drug, in order to explore its possible treatment effect across a range of serious neurologically mediated conditions. We have concentrated on pruritus, cough and movement disorders as the therapeutic areas of interest, since scientific evidence suggests that activity at the mu receptor and the kappa receptor may be significant in these conditions. Severe pruritus in prurigo nodularis is our lead clinical indication — a serious, debilitating skin disease marked by papules and nodules on the skin, along with relentless and severe itching. For this indication, no therapies are approved right now. Prurigo nodularis is chronic, and as a result of repeated scratching, those papules and nodules spread and keep getting worse. Our estimate is that roughly 250,000 PN patients live in the U.S; and 430,000 more are in the rest of the world. A number of biologics are undergoing clinical development for severe pruritus and PN, yet Haduvio is the sole oral therapy being developed for this condition. From where we stand, both biologic medicines and treatments taken by mouth are going to play significant and complementary parts when it comes to treating this severe long-term condition. At this moment, we're conducting our initial Phase 2b/3 study involving these patients who have prurigo nodularis — the trial we refer to as PRISM. Enrollment is underway across the United States and Europe, and as of today, over 60 locations have been switched on. The main goal of the study is a responder analysis tied to how much itch intensity drops, as measured by the Worst Itch Numerical Rating Scale (NRS), with that change looked at after 12 weeks of blinded fixed dosing. Currently, we've randomized roughly 190 patients in this trial, which represents more than half of the final target of 360. On a positive note, over 95% of the participants who finished the blinded dosing phase have decided to continue into the open-label extension part of the trial. In addition, about 30 subjects have now completed the full-year study, which keeps strengthening our long-term safety data and gives us information about how longer treatment might allow skin to heal. Everyone on our team remains dedicated to completing enrollment for this trial while adjusting to the shifting circumstances created by COVID. As far as this study goes, no site we have in the U.S. or the EU is presently holding back on screening or enrolling subjects because of COVID-related restrictions. Regarding enrollment, we are taking multiple recruitment approaches. We leverage things like social platforms to find prospective patients, along with partner websites that help us locate other individuals beyond those already in our system. Beyond that, recent months have kept us occupied with professional gatherings, albeit held online. We recently participated in the 2020 Fall Clinical Dermatology Conference, hosting a virtual booth there that produced more than 300 engagements with our staff, arriving via site visits, leads, live video chats and message board notes. Additionally, two of our e-posters were showcased, and we took part in a shark tank style contest, ending up as the runner up. Back in October, we attended the pruritus symposium held during the virtual meeting of the European Academy of Dermatology and Venereology, known as EADV, where we sponsored a presentation on our Phase 2 trial as well as a discussion about our PRISM trial. Then, this month, we're participating in the Fall Clinical for Dermatology, which serves physician assistants and nurse practitioners, through a virtual booth that promotes our PRISM trial. It's been both educational and a pleasant surprise to see how well the world has adjusted to these virtual medical conferences. Based on the enrollment rates, we're reaffirming our guidance for the PRISM trial: we anticipate finishing enrollment during the third quarter of 2021, with top line data reported in the fourth quarter of 2021. We recognize how serious this condition is, and we understand how much it matters to give patients a pill-based treatment choice. Our ongoing priority is to complete enrollment in this study and to report top line results in about twelve months. Now let's discuss our second clinical phase program, which targets cost and idiopathic pulmonary fibrosis, or IPF. This disease gets worse over time and is severe, involving scar tissue formation in the lungs. A major and debilitating symptom patients experience is persistent coughing, and roughly 70% to 85% of those with the disease deal with it, yet no approved treatments exist for it. We are running a Phase 2 double-blind crossover trial that includes a 14-day washout period following each three-week treatment arm. The main way we're judging results is by looking at how much each patient's daytime cough rate shifts, on average, as a percentage, when they're on the active treatment compared with when they're on placebo. A digital cough monitor is what captures the daytime cough frequency data. Right now, this study is running in the UK, and because these patients face elevated danger of COVID complications given the lung impairment they already have, we halted every screening and enrollment effort back in March. While the study was on hold, our attention went to revising established protocols so we could more reliably and effectively bring patients in despite the pandemic conditions. We submitted a change to the protocol permitting reduced on-site visits along with fewer procedures in total, and we also removed the screening limitations that had applied. The UK's Medicines and Healthcare Products Regulatory Agency, known as MHRA, has now given its approval to that revised protocol. Since then, screening has resumed at certain sites, and a first randomization has been carried out. Several sites are currently engaged in start-up work for the trial and expect to reopen prior to the close of the year. On top of that, Trevi is identifying possible locations for the study in Germany, which might speed up enrollment and lower the danger associated with recruiting from just one nation during the COVID pandemic. A feasibility assessment for Germany has been finished, and multiple sites have shown interest in participating in the study. Through the end of the year, we are arranging qualification visits for those candidate sites, while also addressing regulatory steps needed to include Germany in this study. Several additional programs of ours remain in earlier development phases. Still, by giving priority to our pruritus and cough programs, we can optimize both how we carry out development and our company's resources. At this point, I'll turn things over to Chris Seiter, Chief Financial Officer at Trevi, for a financial update. Chris?
Chris Seiter
executiveThanks, Jennifer. Just a quick note that you can find the complete financial results for 2020's third quarter in our 10-Q, and as we mentioned, we intend to submit that to the SEC tomorrow. Looking at Q3 2020, our net loss came in at $7.4 million, which compares with a net loss of $7.4 million during the same three-month period in 2019. R&D costs reached $4.8 million in that quarter — so, Q3 of 2020 — versus $5.7 million for the equivalent stretch of 2019. That drop stemmed mainly from reduced activity in our Phase 2 trial focused on chronic cough among IPF patients, since enrollment and treatment of those patients were paused because of the COVID-19 pandemic, plus lower activity following completion of our Phase 1b trial involving chronic liver disease patients. On the G&A side, expenses came to $2.4 million in Q3 2020, up against $2 million for the matching period in 2019. This rise largely reflected higher stock-based compensation costs along with greater consulting fees. When September 30, 2020 arrived, our cash and cash equivalents stood at $53.3 million, versus $57.3 million on December 31, 2019. Over the course of that third quarter, we put funding strategies in place drawing on both debt and equity in order to lengthen our cash runway. Also during Q3, roughly $2.5 million worth of our common stock was sold via our ATM facility. Beyond that, during the same quarter, a term loan facility with Silicon Valley Bank brought in $14 million. Money raised through the ATM plus this non-dilutive term loan strengthens our cash position, and we anticipate it will push our cash runway into the first half of 2022 — beyond the expected top line results from the PRISM file, which should arrive in the fourth quarter of 2021. That wraps up what we had prepared. I'll now hand the call back to the operator so we can begin Q&A.
Gary Nachman
analystHi everyone, and good afternoon. You've achieved solid strides on enrollment for PRISM. I'm wondering, how significantly has the rate of enrollment increased since summertime, when you were gaining some traction? Has it been speeding up? Is it decelerating at this point because of the COVID surge? From what it sounds like, you've got a number of efforts underway that you mentioned; and then a quick follow-up on that, Jennifer. Is there any situation in which you could exceed a 360 target if enrollment is going nicely? Or is that certainly the hard ceiling? If you folks wanted to be even more sure, I suppose, regarding the statistical significance in the trial.
Jennifer Good
executiveYes. Two solid questions. Hi, Gary. Great to hear from you. So the rate of enrollment after COVID was robust, certainly a nice bolus during the initial couple of months. I'd say August was somewhat lighter, which isn't surprising. And then autumn has gone well; we're approaching the holiday season, so it'll be a fascinating sort of 1.5 months-ish. I don't — we've got solid screenings happening and individuals in screening, but this is consistently a fascinating stretch of time for direct developers. But I'd say, on average, we've been kind of reaching this 15 to 20 patients each month. And I believe if we continue moving along at that pace, we ought to be in good shape. So that's positive. I think your inquiry about the 360 being the maximum. When you've got roughly 360, usually, as you're aware, from doing this for many years, when you've got individuals in the queue, you generally let them progress their way through. So depending on precisely how many individuals are in the queue, we'll let them complete. But I think based on sort of our staff and our FFRE results, that ought to be a solid number to tease out statistical significance. So we aren't aiming to attempt to overshoot this or upsize it at the conclusion. But if individuals are in the queue, we'll clearly let them complete.
Gary Nachman
analystAll right. If I may, let me fit in just one additional question. Regarding chronic coughs, it seems like things are only just beginning there. Are we still aiming for 56 patients and 44 completers? Or is it truly a function of how many sites are operational in the UK and possibly Germany? And given that this might shift, how much time do you figure it will take to conduct this study now?
Jennifer Good
executiveWhen we submitted our amendment to MHRA, we raised the upper limit of potential patients to 60, which related to a few individuals we had to remove from the trial when we halted it because of COVID; we simply wanted to allow ourselves space to reach our 44 completers. So the number of completers remains unchanged. We merely provided some flexibility regarding how many people you could screen into the study. And Gary, your second question was what? My apologies. Timing.
Gary Nachman
analystYeah. So, what's the timeline for wrapping up this trial? I realize it's hard to predict right now, since it hinges so much on the number of sites you can activate. But if you had to offer a rough estimate at this stage?
Jennifer Good
executiveYeah. No. I told Chris we'd be getting this question. It's difficult to say, because we're standing up our sites out of the UK, getting those operational. We're examining Germany as a way to speed things up. I'm certainly pushing — I really want enrollment done next year. I simply don't believe we have solid visibility into when within that year it happens. So we are putting money in, and we've got the right level of resources devoted to it. I just lack a clear picture of the runway so far. We've randomized our first paycheck back from COVID. And, by the way, Europe is kind of on shaky footing, so it's a hard call. One bright spot I'd point to that came out of this entire COVID situation for us. Some trials that were further along in enrollment had to be halted, and people have simply abandoned the IPF space, not only cough. We did have one rival in cough, Respivant, whose drug failed, which leaves us somewhat in the lead here — that helps. But there's also — plenty of activity was happening in IPF broadly, especially in the UK. And many of those participants haven't returned. So we've witnessed genuine enthusiasm, and we heard that when we visited Germany — folks were keen to restart clinical trials. So I'm hopeful that works in our favor. But it carries the COVID backdrop with it. So we simply aren't yet able to provide solid guidance on that.
Gary Nachman
analystOkay. That’s fair. Thanks a lot.
Jennifer Good
executiveYes.
Ami Fadia
analystHello there, and good evening. I appreciate you taking the question. Jennifer, the enrollment is moving along nicely. Since more patients have been coming in, could you share anything about the dropout rate or what the adverse event profile looks like?
Jennifer Good
executiveSure. Hello, Ami. It's great to hear from you. Regarding dropouts, you're aware that we tend to avoid talking in terms of percentages, since everything remains blinded. That makes it hard to observe. What I can say is that, consistent with what we've stated previously, they fall within a range we would expect. And I believe our sample size reestimation offered a sort of confirmation of that. When it comes to adverse events, we track those as part of what we're required to do; and to me — it appears quite similar to what we saw in our other trials. The usual things like dizziness, somnolence, nausea — nothing unforeseen has emerged during the trial. An independent data monitoring committee is in place. Within this trial, they have convened two times so far, and we could move forward as anticipated. So overall, I'd say it appears very much in line with our other trials and the adverse events we've observed.
Ami Fadia
analystUnderstood. Then regarding the IPF cough program — what's the strategy for advancing that over roughly the coming 12 months while the PN study is still being finished?
Jennifer Good
executiveRight, so there are 2 separate teams; each has its own physician and its own clinical ops group, so they operate independently. That said, we're a small organization, so everyone overlaps somewhat. Resources aren't my concern, though. What I see as difficult in those 2 trials comes down to recruitment and enrollment; both involve small patient populations, and IPF cough definitely has COVID as a backdrop, plus PN to some degree as we go through the winter months. So our attention is really on whatever we can do to help both trials and get patients enrolled, since from a team standpoint we have enough resources. You may have noticed too, Ami, that we did some hiring during the COVID window. We brought on a strong regulatory person, an additional pharmacology person, and another commercial person. There's simply more good strength arriving across the company. I'd also say our clinical team is now fully built out, so I don't feel constrained on resources. It's simply a question of getting them enrolled.
Ami Fadia
analystUnderstood. All right. Perhaps only a final inquiry. And I sense you've kind of provided the response to this, yet I'm simply curious whether there might be any chance regarding how should we consider the second trial in PN? Assuming the initial one proves successful. Might it involve a trial of comparable size given how we're thinking about the duration and assets that could be needed for that second one?
Jennifer Good
executiveYeah. Thus, several of those conversations have already been kicked off by the team; we'd like to find ourselves able to move swiftly into that subsequent trial. And I believe we possess quite a strong capacity for achieving that. Most likely, we will continue working with the same CRO. A team is in place, prepared to begin. Regarding study design, I'd say we're currently discussing a few various alternatives somewhat, though for planning reasons, it's probably a solid assumption to expect approximately an identical count by the conclusion. What I mean is, once the data comes in, clearly, we might adjust the powering somewhat. Still, I'd say from where we stand right now, that's likely a reasonable assumption.
Ami Fadia
analystUnderstood. Alright, thanks.
Jennifer Good
executiveYes — thank you as well, Ami.
Serge Belanger
analystHi there, good afternoon. So I suppose I have a few things to ask, starting with the open-label study for — that includes PRISM. I might have missed this, but is the rollover rate into that trial still sitting in the mid-90% range? And I believe you also said that 30 patients had gotten through the whole extra 38 weeks. At this point, do you have any sense of, I guess, how many patients are — or what share of patients make it to the conclusion of that study? And do they remain on it even after their lesions have healed?
Jennifer Good
executiveYes. So Serge, that's a fair question. So yes, we did say that more than 95% are choosing to roll into the open-label extension. We're achieving good results in getting folks through to the finish. The thing I haven't examined is the second part of what you asked — honestly, we haven't done much analysis of the open-label data, in terms of where people are dropping out and how their skin appears and all of that; so I really can't say much about it. And doing that in isolation from the blinded data is always somewhat risky in any case; but people are remaining on it; they do well on the drug. And clearly, there's good durability of effect of their itch suppression; so I don't know, I haven't really gone through and considered when people leave, is it because their itch is down to a certain level, we'll do that sort of as part of our analysis of the data.
Serge Belanger
analystIs there a specific patient count required to finish that open-label extension trial so you can supply the safety data the FDA wants?
Jennifer Good
executiveYeah. So, as you're likely aware, the ICH guidance calls for 100 — a hundred patients having twelve months of information. From the earlier study, we already had 25, I believe, or perhaps 15 — 15 from the study we did before — and here we've already got 30. So this trial is going to put a big dent in that. There's still quite a distance left to cover, and many individuals are at different points along the way. So I think once this study wraps up, we'll be sitting in good shape. That said, I think if there's another — supposing a second trial has to be conducted, providing that open-label extension is always beneficial since it gives people certainty they'll receive drug at some point at minimum; so our safety database doesn't concern me. And as you're aware, this drug has existed for some time, so there's plenty of knowledge about it. The FDA acknowledges it. So all of that works in our favor. So we appear to be on course to reach every one of those figures.
Serge Belanger
analystOkay. And then just one more thing regarding the IPF cough program. There has been a lot going on lately when it comes to chronic cough. Can you possibly discuss the key distinctions between IPF cough and chronic cough, and is there anything we can take away from those trials regarding response or placebo?
Jennifer Good
executiveYes. It is a captivating area. I have been tracking it too. To me, chronic cough is somewhat like atopic derm is to PN. It is kind of the big gorilla here. First off, I would say, as you are aware, the leading drugs being pursued are P2X3, with various versions of those, and all of them began as pain medications. So that strikes me as interesting. I mean, that appears to be a rather intriguing mechanism, which, as you know, is also kind of where nalbuphine got its start. So I find that compelling. I believe we picked IPF cough due to the neurological mechanism of lung fibrosis triggering the signal, and kind of where the body had plenty of these opioid receptors. So we thought it was the correct spot. It is a progressive disease that is difficult; we have had cough experts reach back to us fairly often, incidentally, interested in studying our drug. Low dose morphine is used now in these patients. So this opioid mechanism is one that is known, and there is interest in it. I think we try to remain in areas that we believe make biological sense and are also an area that we could someday market ourselves in the U.S., if we desired to. Chronic cough turns into a very large primary care cell, not that we would not be interested; but I think with interesting data here, we would determine how to kind of springboard into running a trial into chronic cough. So I mean I am following all the literature about attempting to screen in and have a certain severity of cough, which is not unlike PN. I think we simply have to get through our trial, analyze the data, and then begin looking at it in totality with chronic cough to see what it all means. There is still a great deal to learn in these areas.
Serge Belanger
analystOkay, thanks.
Annabel Samimy
analystThank you for the question — most of them have already been addressed by now. But may I ask you, regarding the second study for PN. Clearly, these programs have a considerable distance to cover before any completion can be observed. Has any consideration been given to launching the second trial prior to receiving data from the first one? Is it simply a matter of risk — attempting to mitigate that risk? Or does it come down more to insufficient resources to run both studies simultaneously?
Jennifer Good
executiveWell, that is a fair question, and it is one that has come up — Chris and I discuss it frequently, and it has been raised at the Board level too. My perspective, Annabel, is that it is not — I mean, clearly, we lack the funds to carry us entirely through an additional pivotal trial. Yet initiating it concurrently has not been ruled out. That said, I hold a fairly strong view that reviewing the results from this trial will allow us to truly fine-tune whatever protocol subtleties exist. And over time, I believe we will in fact recover that time. I am considerably more at ease that for the second trial, to begin with, certain competitive issues we faced will have largely cleared away, which helps. Also, I believe we have gained an understanding, from conducting a trial of this magnitude, of how many sites must be enlisted. We now have connections with more than 65 solid sites across the U.S. and Europe. So as for our protocol, we have essentially resolved whatever problems arose. Thus I believe there is a solid capacity to move swiftly and regain time. I would feel uneasy about kicking off that trial and being committed before we had a chance to review the results from this one. Because I genuinely believe it concerns refining the label and the opportunity, especially given that it is now reasonably apparent how the competitive environment will develop, with biologics and Trevi as the sole oral option. So considering — being deliberate about how you compete in that arena and maximize the product's value, I believe, matters. And I do not wish to race ahead of that and forfeit the chance to refine something in the final trial.
Annabel Samimy
analystOkay, understood. Understood. Also, does anything about the rival programs give you a sense of reassurance? I know your approach targets mixed opioid receptors, even though the Cara product has kind of heard of your kappa agonism. So can you draw any reassurance from what they've done across various indications that would make you feel more confident about how you'll run your trials?
Jennifer Good
executiveYes. I mean, I believe — and as you know, we've discussed this before. In my view, Cara remains the closest comparison to us, since we're a pure kappa agonist. We bind to both receptors. I'd say each matters for different forms of itch; still, I do feel they resemble us the most, and we've always kind of moved away from certain other mechanisms out there. On top of that, we hear plenty of feedback from investigators who prescribe the drug, and much of it is quite encouraging. It encourages me when I see patients remain on it for a year. We receive every sort of anecdotal report. So the mechanism generates excitement among people. I'm eager to reach data. I believe everything comes down to kind of nailing the endpoint and, with luck, running a solid trial. That said, yes, I do feel Cara's data lends support to kind of our mechanism as a whole.
Annabel Samimy
analystAll right. Then, regarding your final question about IPF. Clearly, the trial is being run in the UK, and there may be a launch in Germany as well. We're aware that both countries have some form of lockdown. Is the lockdown there a bit different from others, such that it won't throw your enrollment off track, and are the changes you've implemented to cut down on the number of visits enough to keep the entire program advancing even if pandemic peaks and lockdowns occur?
Jennifer Good
executiveYes, that's a good question. When we previously had to halt everything, those patients were in what is termed the shielding environment; certain patients, including those with IPF, were instructed not to go out of their homes. They aren't under that type of lockdown. They're essentially like what we're observing nearby with bars, restaurants, and similar places. So the sites have informed us that it doesn't affect their capacity to see these patients; they all must have the proper protocols in place; and we established some procedures so patients can be seen, they're allowed to miss visits, we removed visits. So I hope that's the case, Annabel, but if the situation deteriorates and this is a difficult patient population; so we'll need to keep an eye on it. But the present lockdown measures do not revert to the shielding, which is what caused the pause previously.
Annabel Samimy
analystAll right, excellent. Thanks very much.
Jennifer Good
executiveChris and I want to express our appreciation to everyone who joined us on today's call. Our gratitude also goes out to the Trevi team, the investigators on our studies, and every subject who keeps taking part in our clinical trials through these difficult circumstances; we're eager for ongoing advancement and to bring you an update before long. Make the most of what remains of this year, and do take care of yourselves. Thanks so much.
Operator
operatorWe appreciate your taking part in the call today; that brings the program to an end. You are free to disconnect now. Have a wonderful day, everyone.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.